secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001140361-24-027986
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports FY2024 GAAP income from continuing ops $4.2B on $5.3B Telavant gain; Q4 loss $182.5M
--------------------------------------------------------------------------------

- Net product revenue from VTAMA (psoriasis) $75.1M for FY2024; over 385K prescriptions since launch.
- Cash, cash equivalents and restricted cash $6.6B at March 31, 2024; after $648.4M share repurchase from Sumitomo, pro forma $5.9B.
- Non-GAAP loss from continuing operations $799.9M for FY2024 vs $924.3M prior year.
- Dermavant debt renegotiated reducing potential payments by over $300M; $225M reduction expected over next three fiscal years.
- Pipeline: Priovant to initiate pivotal brepocitinib trial in NIU in H2 2024; Immunovant expects 4-5 registrational studies by March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124027986/0001140361-24-027986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124027986/ef20030255_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-027986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer